Anthrax Therapeutics - Pipeline Analysis 2018

Anthrax Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11171
Available Format:

Anthrax is an infectious disease caused by rod-shaped, gram-positive bacteria known as Bacillus anthracis. Anthrax can be found naturally in soil and commonly affects domestic and wild animals globally. It has been observed that people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. Contact with anthrax can cause severe illness in both humans and animals. Domestic and wild animals such as cattle, antelope, deer, goats and sheep can become infected when they breathe in or ingest spores in contaminated plants, soil, or water. In areas where domestic animals have had anthrax in the past, routine vaccination can help prevent outbreaks. The antibiotics also used for the treatment of anthrax, includes Quinolones, amoxicillin, ciprofloxacin or doxycycline, Raxibacumab, and Anthrasil.

The drug candidates in the anthrax pipeline include, but are not limited to, Ciprofloxacin inhalation, anthrax vaccine and rPA 102. Some of the companies having drugs candidates in the pipeline for treating anthrax include Altimmune, Aradigm Corporation and NanoBio Corporation.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry